Cytogenetic Remissions Induced by Interferon α and Imatinib Mesylate are Immunologically Distinct in Chronic Myeloid Leukemia - Nakayama, Shin; Nagamura-Inoue, Tokiko; Yokoyama, Kazuaki; Ohno, Nobuhiro; Ooi, Jun; Takahashi, Satoshi; Uchimaru, Kaoru; Iseki, Toru; Tojo, Arinobu (International journal of hematology, 2007)
Keywords: Adult; Aged; Antineoplastic Agents - administration & dosage; B-Lymphocytes - immunology; Benzamides; Biological and medical sciences; CD4-CD8 Ratio; CML; Cytogenetic remission; Female; Hematologic and hematopoietic diseases; Hematopoiesis - drug effects; Hematopoiesis - immunology; Humans; Imatinib Mesylate; Immunoglobulin A - blood; Immunoglobulin A - immunology; Immunoglobulin G - blood; Immunoglobulin G - immunology; Immunologic Factors - administration & dosage; Interferon α; Interferon-alpha - administration & dosage; Killer Cells, Natural - immunology; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - blood; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - immunology; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis; Male; Medical sciences; Middle Aged; Monocytes - immunology; Piperazines - administration & dosage; Pyrimidines - administration & dosage; Recovery of Function - drug effects; Recovery of Function - immunology; Remission Induction; Antineoplastic agent; Imatinib; CML; Hematology; Enzyme; Alpha interferon; Transferases; Imatinib mesylate; Enzyme inhibitor; Chronic myelogenous leukemia; Malignant hemopathy; Interferon α; Myeloproliferative syndrome; Cytogenetic remission; Cytogenetics; Remission; Protein-tyrosine kinase